# Fexofenadine protects against osteoarthritis by targeting Smad2 and STAT1 to enhance anabolism and binding cPLA2 to inhibit catabolism

**Authors:** Kaiwen Liu, Xiaodi Zhang, Bin Ning, Ronghan Liu, Cheng Wang, Lei Cheng, Weiwei Zheng, Jianlu Wei

PMC · DOI: 10.1038/s41420-025-02754-9 · Cell Death Discovery · 2025-10-21

## TL;DR

Fexofenadine, an allergy drug, protects cartilage in osteoarthritis by reducing inflammation and boosting tissue repair through specific molecular targets.

## Contribution

The study identifies FFD as a novel therapeutic for OA by targeting Smad2 and STAT1, offering new treatment insights.

## Key findings

- FFD reduces inflammation by binding to cPLA2 and inhibiting NF-κB activation.
- FFD enhances cartilage anabolism by targeting STAT1 and Smad2 to promote TGFβ signaling.
- FFD shows therapeutic effects in both human ex-vivo cultures and murine OA models.

## Abstract

Cartilage metabolism balance chaos is crucial in the development and progression of osteoarthritis (OA), with chronic low-grade inflammation being the primary factor that leads to chondrocyte metabolic dysregulation. Fexofenadine (FFD) is a widely used commercially available anti-allergy compound, which has been shown to reduce inflammation. The present study finds FFD’s therapeutic effects in primary human ex-vivo cultures and surgically induced murine models. Mechanism study illustrates FFD exhibits chondroprotective effect through anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated inflammation and pro-Transforming Growth Factor Beta (TGFβ)-associated anabolism. Specifically, FFD directly binds to cytosolic phospholipase A2 (cPLA2), down-regulating downstream NF-κB activation, resulting in alleviated catabolism. Notably, Signal Transducer and Activator of Transcription 1 (STAT1) is first identified as FFD’s target by Drug affinity responsive target stability which shows the Gln-314 site is required. FFD blocks STAT1 binds to TGF-β type I receptor, leading to secondary SMAD Family Member 2 (Smad2) phorsphorylation, slightly enhances chondrocyte proliferation and matrix production. Importantly, further study demonstrates FFD directly binds Smad2 by the target proteins fishing technique, remarkably active TGFβ-related biological process. These findings provide new insights into the chondroprotective role of FFD with novel target and downstream pathway, offering promising avenues for the treatment of OA.

Mechanism of Fexofenadine in treating osteoarthritis. Created with BioRender.com.

Mechanism of Fexofenadine in treating osteoarthritis. Created with BioRender.com.

## Linked entities

- **Genes:** STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772], SMAD2 (SMAD family member 2) [NCBI Gene 4087], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], PLA2G4A (phospholipase A2 group IVA) [NCBI Gene 5321]
- **Chemicals:** Fexofenadine (PubChem CID 3348)
- **Diseases:** osteoarthritis (MONDO:0005178)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PLA2G4A (phospholipase A2 group IVA) [NCBI Gene 5321] {aka GURDP, PLA2G4, cPLA2, cPLA2-alpha}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** inflammation (MESH:D007249), OA (MESH:D010003), allergy (MESH:D004342)
- **Chemicals:** FFD (MESH:C093230)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12540828/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12540828/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12540828/full.md

---
Source: https://tomesphere.com/paper/PMC12540828